Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-106675

ABSTRACT: Intragraft molecular pathways associated with tolerance induction in renal transplantation

PROVIDER: E-GEOD-106675 | ExpressionAtlas | 2025-01-16

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-106675-analysis-methods.tsv	Tabular
	E-GEOD-106675-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-106675-configuration.xml	Xml
	E-GEOD-106675-percentile-ranks.tsv	Tabular
	E-GEOD-106675.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 57

Similar Datasets

Intragraft molecular pathways associated with tolerance induction in renal transplantation

Project description:Intragraft molecular pathways associated with tolerance induction in renal transplantation

| PRJNA417593 | ENA

E-GEOD-9493

Project description:Transcriptomic analyses of renal allograft biopsies reveal conserved rejection signatures and molecular pathways

2025-01-24 | E-GEOD-9493 | ExpressionAtlas

E-GEOD-32384

Project description:Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation

2025-01-24 | E-GEOD-32384 | ExpressionAtlas

E-GEOD-14346

Project description:A peripheral blood diagnostic test for acute rejection in renal transplantation.

2025-01-24 | E-GEOD-14346 | ExpressionAtlas

E-GEOD-22229

Project description:Identification of a B cell signature associated with renal transplant Tolerance in humans

2025-01-24 | E-GEOD-22229 | ExpressionAtlas

E-GEOD-31977

Project description:Transcriptome profiling identified genes and pathways associated with arsenic toxicity and tolerance in Arabidopsis

2015-06-01 | E-GEOD-31977 | ExpressionAtlas

E-GEOD-46699

Project description:Smoking and Obesity Related Molecular Alterations in Clear Cell Renal Cell Carcinoma

2025-01-24 | E-GEOD-46699 | ExpressionAtlas

GENOMICS TO IDENTIFY HLA IDENTICAL RENAL TRANSPLANT TOLERANCE SIGNATURES

Project description:Immunosuppression is needed in HLA identical sibling renal transplantation. We conducted a tolerance trial in this patient cohort using Alemtuzumab induction, donor hematopoietic stem cells, tacrolimus/mycophenolate immunosuppression converted to sirolimus, planning complete drug withdrawal by 24 months post-transplantation. After an additional 12 months with no immunosuppression, normal biopsies and renal function, recipients were considered tolerant. Twenty recipients were enrolled. Of the first 10 (>36 months post-transplantation), 5 had immunosuppression successfully withdrawn for 16-36 months (tolerant), 2 had disease recurrence and 3 had subclinical rejection in protocol biopsies (non-tolerant). Microchimerism disappeared after 1 year, and CD4+CD25highCD127-FOXP3+ T cells and CD19+IgD/M+CD27- B cells increased to 5 years post-transplantation in both groups, whereas immune/inflammatory gene expression pathways in the peripheral blood and urine were differentially downregulated in tolerant compared to non-tolerant recipients. Therefore, in this HLA identical renal transplant tolerance trial, absent chimerism, Treg and Breg immunophenotypes were indistinguishable between tolerant and non-tolerant recipients, but global genomic changes indicating immunomodulation were observed only in tolerant recipients.

2013-04-01 | GSE45593 | GEO

Gene expression profiling in B lymphocytes from transplanted patients

Project description:The achievement of a drug-free operational tolerance for renal transplanted patients is a major goal in organ transplantation. Previous gene expression profiling in peripheral blood mononuclear cells (PBMC) identified genes associated with operational tolerance. The identification of a common pattern of B cell-related genes associated with tolerance encourage us to analyze gene expression in purified B cell from operationally tolerant patients (TOL=10) compared to renal transplanted patients with stable graft function (STA=12) under immunosuppression and also compared to healthy volunteers (HV=10) who have no immunosuppressive treatment and no graft. Microarray analyses exhibited an absence of gene signature associated with tolerance in purified B cell compared to STA or HV. These results suggest that the B cell signatures observed in PBMC may be due to an increase number of total B cells rather than specific B cell characteristics in operationally tolerant patients. This dataset represents gene expression profiling of purified B cells from 10 renal transplanted patients with operational tolerance (TOL), 12 renal transplanted patients with stable graft function under immunosuppression (STA) and 10 healthy volunteers (HV).

2015-08-01 | E-GEOD-39899 | biostudies-arrayexpress

Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation (miRNome analysis)

Project description:Although Tacrolimus is an immunosuppressive drug widely used in renal transplantation, its chronic use paradoxically induces nephrotoxic effects, in particular renal fibrosis, which is responsible for chronic allograft dysfunction and represents a major prognostic factor of allograft survival. As molecular pathways and mechanisms involved in Tacrolimus-induced fibrogenic response are poorly elucidated, we assessed whether miRNAs are involved in the nephrotoxic effects mediated by Tacrolimus. Treatment of CD-1 mice with Tacrolimus (1mg/kg/d for 28 days) resulted in kidney injury and was associated with alteration of a gene expression signature associated with cellular stress, fibrosis and inflammation. Tacrolimus also affected renal miRNA expression, including miRNAs previously involved in fibrotic and inflammatory processes including “fibromirs” such as miR-21-5p. Specifically, Renal Proximal Tubular Epithelial cells exposed to tacrolimus showed up-regulation of miR-21-5p and the concomitant induction of epithelial phenotypic changes, inflammation and oxidative stress. In conclusion, this study suggests for the first time that miRNAs, especially fibromiRs, mediate Tacrolimus-induced nephrotoxic effects.

2018-02-06 | GSE102514 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data